Added value of serum proteins to clinical and ultrasound information in predicting the risk of malignancy in ovarian tumors
View ORCID ProfileA Coosemans, View ORCID ProfileJ Ceusters, C Landolfo, T Baert, W Froyman, R Heremans, G Thirion, S Claes, J Oosterlynck, R Wouters, A Vankerckhoven, F Moro, F Mascilini, A Neumann, AS Van Rompuy, D Schols, J Billen, T Van Gorp, I Vergote, T Bourne, C Van Holsbeke, V Chiappa, G Scambia, A Testa, D Fischerova, D Timmerman, View ORCID ProfileB Van Calster
doi: https://doi.org/10.1101/2024.03.14.24304282
A Coosemans
1Department of Oncology, Laboratory of Tumor Immunology and Immunotherapy, Leuven Cancer Institute, KU Leuven, Leuven, Belgium
J Ceusters
1Department of Oncology, Laboratory of Tumor Immunology and Immunotherapy, Leuven Cancer Institute, KU Leuven, Leuven, Belgium
C Landolfo
1Department of Oncology, Laboratory of Tumor Immunology and Immunotherapy, Leuven Cancer Institute, KU Leuven, Leuven, Belgium
2Department of Development and Regeneration, KU Leuven, Leuven, Belgium
3Queen Charlotte’s and Chelsea Hospital, Imperial College, London, UK
4Dipartimento Scienze della Salute della Donna, del Bambino e di Sanità Pubblica, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome, Italy
T Baert
5Department of Obstetrics and Gynaecology, University Hospitals Leuven, Leuven, Belgium
6Department of Oncology, Gynaecological Oncology, Leuven Cancer Institute, KU Leuven, Leuven, Belgium
W Froyman
2Department of Development and Regeneration, KU Leuven, Leuven, Belgium
5Department of Obstetrics and Gynaecology, University Hospitals Leuven, Leuven, Belgium
R Heremans
2Department of Development and Regeneration, KU Leuven, Leuven, Belgium
G Thirion
1Department of Oncology, Laboratory of Tumor Immunology and Immunotherapy, Leuven Cancer Institute, KU Leuven, Leuven, Belgium
S Claes
7Department of Microbiology, Immunology and Transplantation, Laboratory of Virology and Chemotherapy (Rega Institute), KU Leuven, Leuven, Belgium
J Oosterlynck
8Department of Laboratory Medicine, University Hospitals Leuven, Leuven, Belgium
R Wouters
1Department of Oncology, Laboratory of Tumor Immunology and Immunotherapy, Leuven Cancer Institute, KU Leuven, Leuven, Belgium
9Oncoinvent AS, Oslo, Norway
A Vankerckhoven
1Department of Oncology, Laboratory of Tumor Immunology and Immunotherapy, Leuven Cancer Institute, KU Leuven, Leuven, Belgium
F Moro
4Dipartimento Scienze della Salute della Donna, del Bambino e di Sanità Pubblica, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome, Italy
F Mascilini
4Dipartimento Scienze della Salute della Donna, del Bambino e di Sanità Pubblica, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome, Italy
A Neumann
10Gynecologic Oncology Centre, Department of Gynecology, Obstetrics and Neonatology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
AS Van Rompuy
11Department of Pathology, University Hospitals Leuven, Leuven, Belgium
D Schols
7Department of Microbiology, Immunology and Transplantation, Laboratory of Virology and Chemotherapy (Rega Institute), KU Leuven, Leuven, Belgium
J Billen
8Department of Laboratory Medicine, University Hospitals Leuven, Leuven, Belgium
T Van Gorp
5Department of Obstetrics and Gynaecology, University Hospitals Leuven, Leuven, Belgium
6Department of Oncology, Gynaecological Oncology, Leuven Cancer Institute, KU Leuven, Leuven, Belgium
I Vergote
5Department of Obstetrics and Gynaecology, University Hospitals Leuven, Leuven, Belgium
6Department of Oncology, Gynaecological Oncology, Leuven Cancer Institute, KU Leuven, Leuven, Belgium
T Bourne
2Department of Development and Regeneration, KU Leuven, Leuven, Belgium
3Queen Charlotte’s and Chelsea Hospital, Imperial College, London, UK
C Van Holsbeke
12Department of Obstetrics and Gynecology, Ziekenhuis Oost-Limburg, Genk, Belgium
V Chiappa
13Department of Gynecologic Oncology, National Cancer Institute of Milan, Milan, Italy
G Scambia
4Dipartimento Scienze della Salute della Donna, del Bambino e di Sanità Pubblica, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome, Italy
A Testa
2Department of Development and Regeneration, KU Leuven, Leuven, Belgium
4Dipartimento Scienze della Salute della Donna, del Bambino e di Sanità Pubblica, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome, Italy
D Fischerova
10Gynecologic Oncology Centre, Department of Gynecology, Obstetrics and Neonatology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
D Timmerman
2Department of Development and Regeneration, KU Leuven, Leuven, Belgium
5Department of Obstetrics and Gynaecology, University Hospitals Leuven, Leuven, Belgium
B Van Calster
2Department of Development and Regeneration, KU Leuven, Leuven, Belgium
14Department of Biomedical Data Sciences, Leiden University Medical Centre (LUMC), Leiden, Netherlands
15Leuven Unit for Health Technology Assessment Research (LUHTAR), KU Leuven, Leuven, Belgium
Data Availability
The pseudonymized data and data dictionary is stored in the KU Leuven Research Data Repository (RDR), https://doi.org/10.48804/TXL95Z. The dataset is not publicly available because this was not part of the informed consent. However, the dataset may be obtained following permission of prof. AC (an.coosemans{at}kuleuven.be) and prof. DT (dirk.timmerman{at}uzleuven.be) and after fulfilling all data transfer requirements.
Posted March 15, 2024.
Added value of serum proteins to clinical and ultrasound information in predicting the risk of malignancy in ovarian tumors
A Coosemans, J Ceusters, C Landolfo, T Baert, W Froyman, R Heremans, G Thirion, S Claes, J Oosterlynck, R Wouters, A Vankerckhoven, F Moro, F Mascilini, A Neumann, AS Van Rompuy, D Schols, J Billen, T Van Gorp, I Vergote, T Bourne, C Van Holsbeke, V Chiappa, G Scambia, A Testa, D Fischerova, D Timmerman, B Van Calster
medRxiv 2024.03.14.24304282; doi: https://doi.org/10.1101/2024.03.14.24304282
Added value of serum proteins to clinical and ultrasound information in predicting the risk of malignancy in ovarian tumors
A Coosemans, J Ceusters, C Landolfo, T Baert, W Froyman, R Heremans, G Thirion, S Claes, J Oosterlynck, R Wouters, A Vankerckhoven, F Moro, F Mascilini, A Neumann, AS Van Rompuy, D Schols, J Billen, T Van Gorp, I Vergote, T Bourne, C Van Holsbeke, V Chiappa, G Scambia, A Testa, D Fischerova, D Timmerman, B Van Calster
medRxiv 2024.03.14.24304282; doi: https://doi.org/10.1101/2024.03.14.24304282
Subject Area
Subject Areas
- Addiction Medicine (386)
- Allergy and Immunology (701)
- Anesthesia (193)
- Cardiovascular Medicine (2859)
- Dermatology (244)
- Emergency Medicine (431)
- Epidemiology (12569)
- Forensic Medicine (10)
- Gastroenterology (807)
- Genetic and Genomic Medicine (4447)
- Geriatric Medicine (402)
- Health Economics (716)
- Health Informatics (2856)
- Health Policy (1050)
- Hematology (376)
- HIV/AIDS (893)
- Medical Education (415)
- Medical Ethics (114)
- Nephrology (464)
- Neurology (4201)
- Nursing (223)
- Nutrition (617)
- Oncology (2205)
- Ophthalmology (626)
- Orthopedics (254)
- Otolaryngology (319)
- Pain Medicine (269)
- Palliative Medicine (83)
- Pathology (488)
- Pediatrics (1172)
- Primary Care Research (483)
- Public and Global Health (6787)
- Radiology and Imaging (1494)
- Respiratory Medicine (902)
- Rheumatology (430)
- Sports Medicine (369)
- Surgery (473)
- Toxicology (57)
- Transplantation (202)
- Urology (174)